The nascent Texas Ibogaine Program Needs More Than a Trial. It Needs an Evidence Engine, it Needs Ignite Synergy

WHAT IS IBOGAINE?

Ibogaine is an age-old natural psychoactive compound with psychedelic properties found in the iboga plant, a shrub that is native to Central and West Africa. Western scientists have been studying ibogaine, for its potential in treating drug addiction, PTSD and brain trauma.

TEXAS, SB 2308, AND A STATEWIDE TRIALS FRAMEWORK

Here in the U.S., Ibogaine is attracting national attention because it may help address some of the most serious problems in behavioral health—especially opioid use disorder and treatment-resistant conditions—where current approaches often fall short. Fortunately, the state of Texas is now moving ibogaine into an unprecedented accountable, statewide clinical-trials framework.

HHSC, CONSORTIUM GRANTS, AND $100 MILLION

Legislators have approved Senate Bill 2308 which tasks the Texas Health and Human Services Commission (HHSC) to create an HHSC-administered grant program to form a consortium for FDA drug-development clinical trials with ibogaine. In a recent Joe Rogan podcast, ibogaine advocates Rick Perry and W. Bryan Hubbard announced that the State of Texas has committed a $100 million stand-alone appropriation to develop the program. Perry, former Texas Governor and former U.S. Secretary of Energy and Hubbard, Chief Executive Officer of Americans for Ibogaine, are high profile standard bearers for the movement to address treatment for Americans suffering trauma, addictions, PTSD, and other mental health afflictions through the medical use of ibogaine.

RAISING THE BAR FOR PSYCHEDELIC CLINICAL TRIALS

Naturally, Texas has a complex mission ahead, employing the highest standards of rigorous trials, safety-first operations, and evidence-based results that are transparently accountable throughout the entire process. Clearly, Texas is raising the bar for how psychoactive/psychedelic clinical trials should be run.

WHERE IGNITE SYNERGY FITS

Here is where Ignite Synergy enters the picture with an end-to-end, instantly available development vehicle for this entire project evolution. Synergy App is already built for psychedelics study workflows. We can quickly deploy a “Program OS + Reporting Pack” that gives the Texas HHSC and consortium partners the clinical trials structure and evidence engine this program requires.

STANDARDIZATION AND REPORTING: WHAT THE PROGRAM REQUIRES

This ibogaine development program uniquely depends upon standardization and reporting:

• consistent data capture across institutions
• protocol and safety workflows that are precise and reviewable
• fast, repeatable reporting for HHSC oversight
• a de-identified dataset the state can govern over time

In short: Texas needs an end-to-end evidence engine—not a collection of spreadsheets and one-off exports.

OPERATIONAL COMPLEXITY BEYOND GENERIC EHRS

Ibogaine programs will bring real operational complexity: long sessions, multi-role staffing, chain-of-custody expectations, adverse event tracking, and rigorous follow-up. Traditional electronic health records (EHRs) and generic trial tooling were not designed for that combination, especially when the monitoring/reporting must roll up across sites.

SYNERGY APP: PROGRAM OS + REPORTING PACK FOR SB 2308

Again, Synergy App was built for specific workflows from the ground up (extended sessions, dyad staffing, inventory + traceability, and compliance-minded reporting). For SB 2308 implementation, we position it as a Program OS + Reporting Pack—reducing burden on trial sites while increasing transparency for HHSC.

INVOLVED IN SB 2308? LET’S TALK

Finally, if you and/or your organization are involved in the SB 2308 implementation, consortium formation, site operations, or reporting oversight, let’s talk.